Daclatasvir
- Generic Name
- Daclatasvir
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C40H50N8O6
- CAS Number
- 1009119-64-5
- Unique Ingredient Identifier
- LI2427F9CI
- Background
Daclatasvir is a direct-acting antiviral agent against Hepatitis C Virus (HCV) used for the treatment of chronic HCV genotype 1 and 3 infection. It is marketed under the name DAKLINZA and is contained in daily oral tablets as the hydrochloride salt form . Hepatitis C is an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a si...
- Indication
Indicated for use with sofosbuvir, with or without ribavirin, for the treatment of chronic HCV genotype 1a/b or 3 infection. The dosing regimen of 60mg daclatasvir 60 mg with 400mg sofosbuvir once a day is recommended for both genontypes.
...
- Associated Conditions
- Chronic Hepatitis C - Genotype 3, Chronic Hepatitis C Genotype 1, Chronic Hepatitis C Virus (HCV) Infection, Chronic hepatitis C genotype 2
- Associated Therapies
- -
Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients
- First Posted Date
- 2020-08-04
- Last Posted Date
- 2020-12-03
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 100
- Registration Number
- NCT04497649
- Locations
- 🇪🇬
Cairo and Tanta Universitities, Tanta, Egypt
Sofosbuvir in Treatment of COVID 19
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 60
- Registration Number
- NCT04460443
- Locations
- 🇪🇬
Sherief Abd-Elsalam, Tanta, Egypt
Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection
- Conditions
- Interventions
- First Posted Date
- 2019-07-15
- Last Posted Date
- 2020-05-04
- Lead Sponsor
- Atea Pharmaceuticals, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT04019717
- Locations
- 🇲🇩
Clinical Trial Site, Chisinau, Moldova, Republic of
Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food Intake and Drug-Drug Interactions With Other Antiviral Drugs
- Conditions
- Interventions
- First Posted Date
- 2018-10-16
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Viriom
- Target Recruit Count
- 36
- Registration Number
- NCT03706898
- Locations
- 🇷🇺
Regional State Budgetary Healthcare Institution "Smolensk Regional Clinical Hospital", Smolensk, Russian Federation
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
- Conditions
- Interventions
- First Posted Date
- 2018-09-27
- Last Posted Date
- 2018-10-12
- Lead Sponsor
- Mohamed Raslan
- Target Recruit Count
- 20
- Registration Number
- NCT03686722
- Locations
- 🇪🇬
Drug research centre, Cairo, Egypt
Comparative Study of Two Regiemns in Management of Sofosbuvir/Daclatasvir Failure
- Conditions
- Interventions
- First Posted Date
- 2018-06-08
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 40
- Registration Number
- NCT03549832
- Locations
- 🇪🇬
Assiut University Hopsital, Assiut, Egypt
Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) Infection
- Conditions
- Interventions
- First Posted Date
- 2018-04-04
- Last Posted Date
- 2021-04-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 5
- Registration Number
- NCT03487848
- Locations
- 🇪🇸
Local Institution, Barcelona, Spain
Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Daclatasvir in Treatment-Naїve Patients With Chronic Hepatitis C Genotype 1b
- Conditions
- Interventions
- First Posted Date
- 2018-04-02
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- R-Pharm
- Target Recruit Count
- 105
- Registration Number
- NCT03485846
- Locations
- 🇷🇺
FBIS CSRI of Epidemiology of Federal Service on Customers, Moscow, Russian Federation
🇷🇺St. Petersburg SBHI Center of Prevention and Fight against AIDS and Infection Diseases, Saint Petersburg, Russian Federation
🇷🇺SBEI HPE Moscow State Medical and Dental University n.a. A.I. Evdokimov of Ministry of Health of Russia, Moscow, Russian Federation
Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C]
- Conditions
- Interventions
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2021-05-18
- Lead Sponsor
- Johns Hopkins Bloomberg School of Public Health
- Target Recruit Count
- 150
- Registration Number
- NCT03480932
- Locations
- 🇮🇳
YR Gaitonde Centre for AIDS Education and Johns Hopkins University Collaborative Integrated Care Center (YRG-JHU ICC), Bilaspur, Chhattisgarh, India
Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAV
- First Posted Date
- 2016-12-29
- Last Posted Date
- 2019-01-09
- Target Recruit Count
- 70
- Registration Number
- NCT03004625
- Locations
- 🇨🇳
Kaohsiung Medical Universsity, Kaohsiung, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.